RecruitingPhase 1NCT07363590
A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
Studying Autosomal systemic lupus erythematosus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- MK-1045(biological)
- Enrollment
- 21 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2026 – 2029
Study locations (8)
- Anima Diepenbeek ( Site 0601), Diepenbeek, Limburg, Belgium
- Arensia Exploartory Medicine ( Site 1301), Tbilisi, Georgia
- Istituto Clinico Humanitas- IRCCS ( Site 1902), Rozzano, Milano, Italy
- The University of Tokyo Hospital ( Site 0301), Bunkyo, Tokyo, Japan
- Keio University Hospital ( Site 0302), Shinjyuku, Tokyo, Japan
- PMSI Republican Clinical Hospital "T.Mosneaga" ( Site 1001), Chisinau, Moldova
- ARENSIA Clinics ( Site 0902), Bucharest, Bucharest, Romania
- ARENSIA Exploratory Medicine-Country Emergency Hospital- Arensia,Cluj-Napoca ( Site 0901), Cluj-Napoca, Cluj, Romania
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07363590 on ClinicalTrials.govOther trials for Autosomal systemic lupus erythematosus
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07447986To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus ErythematosusHangzhou Sumgen Biotech Co., Ltd.
- RECRUITINGPHASE3NCT07201129A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular TreatmentViatris Innovation GmbH
- RECRUITINGPHASE1NCT07276958A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)Eli Lilly and Company
- RECRUITINGPHASE1, PHASE2NCT07348055A Study of GR1803 in Systemic Lupus ErythematosusGenrix (Shanghai) Biopharmaceutical Co., Ltd.
- RECRUITINGNCT07000110Anifrolumab Malignancy and Serious Infections StudyAstraZeneca
- RECRUITINGPHASE1NCT07318259Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLEChongqing Precision Biotech Co., Ltd
- RECRUITINGPHASE1NCT07331467Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLEChongqing Precision Biotech Co., Ltd
- RECRUITINGNCT07175285A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 ImmunosuppressantsBristol-Myers Squibb